Jon Quast
speaker
8,197 appearances
81 recordings
2 series
first heard Oct 2025
last heard 6d ago
Jon Quast’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 81 in all, peaking in Aug 2026 with 10.
Appearances
It's always good to balance our perspectives on a company.
But let's go ahead and turn now to Flex, the other company that is being added here to the S&P 500.
Basically, I want you to talk, Matt, explain to us what Flex is and whether or not you think it could be a hidden gem stock.
Well, and thanks for pointing out that spinoff, because one of the things that we do look for in a hidden gem, a potential hidden gem, is something that's misunderstood by the market.
And certainly a spinoff can be something that is misunderstood when you're trying to calculate that value.
However, you're alluding to the fact that perhaps you believe that this stock is overvalued going into it, and that may diminish some return potential here.
So, Rachel, I want you to agree or disagree with Matt's premise here of flex stock being...
Slightly overvalued, overvalued.
What do you think?
All right.
Well, when we come back, we're going to pivot and we're going to go into the mailbag to talk about a health care stock question that was submitted.
You're listening to Motley Fool Hidden Gems Investing.
Welcome back to Motley Fool Hidden Gems Investing.
We certainly love taking mailbag questions whenever we can.
And this question I wanted to throw to Rachel here because healthcare is kind of a little bit more her circle, her area that she spends a lot of time for sure.
And so let me, this question actually has two parts.
So I'm just gonna read the first part here and then I'll read the second part in a bit.
But this is from Drew, says, love the podcast.
Thank you very much.
I've been highly unimpressed by Bristol-Myers Squibb for years now.
Showing 3421–3440 of 8,197 · page 172 of 410
← Previous
Next →